Direct answers
Ipamorelin questions, answered from the cited record
Twenty-two of the most-asked questions about detection, regulation, effects, and the CJC-1295 combination — each answered briefly and sourced.
Is ipamorelin banned by WADA?
Yes. Growth hormone secretagogues including ipamorelin are prohibited in sport at all times under the World Anti-Doping Agency Prohibited List, category S2. Detection is well established: a validated nano-LC method coupled to Orbitrap mass spectrometry screens ipamorelin in human urine down to 2-10 pg/mL [7], one of several accredited assays covering it [9].
Can ipamorelin be detected in a drug test?
In anti-doping testing, yes — though not in a standard workplace panel. Accredited laboratories use mass-spectrometry methods that detect ipamorelin in urine at picogram-per-millilitre concentrations [7]. Its short ~2-hour terminal half-life in humans [2] narrows the detection window, but validated methods reliably identify the parent peptide and its metabolites [9][10].
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively triggers growth hormone release by activating the ghrelin receptor. Its founding 1998 study showed potent growth-hormone release in rats and swine without raising cortisol even at 200-fold its growth-hormone threshold [1] — the selectivity that defines it. It has never been approved as a drug.
What does ipamorelin do for you?
In studies, ipamorelin triggers a single pulse of growth hormone without raising cortisol [1], and in humans that pulse peaks about 40 minutes after dosing [2]. In rats it speeds bone growth [4]. Reported real-world effects — better sleep, faster recovery — are anecdotal and unverified by trials. It has no proven human therapeutic benefit; its one efficacy trial failed [3].
What is ipamorelin peptide?
Ipamorelin peptide is the wholly synthetic pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from the older peptide GHRP-1 and stabilized against enzymatic breakdown. Molecular formula C38H49N9O5, weight about 711.9 daltons. It is not made by the body; it mimics ghrelin at the ghrelin receptor to release growth hormone, established as the first selective growth hormone secretagogue in 1998 [1].
What are the risks of ipamorelin?
The documented risks are mostly gaps and class-level signals. The only Phase 2 trial showed no compound-specific safety signal in a 7-day window [3], but no long-term human safety data exist. A related ghrelin-receptor agonist caused heart-muscle degeneration in rats over 28 days [6], and the growth-hormone axis raises theoretical concerns around IGF-1 and glucose [4][13]. Research-grade purity is also unverified [17].
Does ipamorelin reduce belly fat?
There is no controlled human trial showing ipamorelin reduces belly fat. Community reports describe a gradual, subtle lean-out over weeks to months, but those are anecdotal and confounded by diet and training. In a 2024 ferret study, ipamorelin blunted chemotherapy-driven weight loss by about 24% [5] — a weight-preserving effect in cachexia, not a fat-loss finding. Recent reviews classify it as investigational [17].
What are the downsides of ipamorelin?
The central downside is that it has no proven benefit: its only Phase 2 trial, for postoperative ileus, missed its primary endpoint (25.3 vs 32.6 hours, p=0.15) [3]. Reported side effects include facial flushing, hunger, tingling, and mild water retention — all anecdotal. Structural concerns include unverified research-grade purity [17] and a class-level cardiac signal from a related compound [6].
Why is ipamorelin being discontinued?
Ipamorelin was never an approved, marketed drug, so there is no approval to discontinue. Its clinical development effectively ended after the only Phase 2 trial — for postoperative ileus — missed its primary endpoint and no further trials followed [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access [11].
What does CJC-1295 and ipamorelin do?
The CJC-1295 and ipamorelin combination pairs a growth-hormone-releasing-hormone analog (CJC-1295) with a ghrelin-receptor agonist (ipamorelin) to raise growth hormone through two complementary mechanisms [1]. A 2020 andrology review discusses where such secretagogues sit in practice and the gap between their marketing and any approved indication [11]. No controlled trial has tested the combination for any clinical outcome.
Does ipamorelin increase IGF-1?
Not always, and not in the short term. In the 15-day rat bone-growth study, ipamorelin raised bone growth with no measurable change in total IGF-1 [4], suggesting a partly local, pulse-driven effect. Over sustained protocols, growth-hormone-axis activation is mechanistically linked to IGF-1 elevation [1], which underlies the theoretical cancer caution — but ipamorelin-specific long-term human IGF-1 data do not exist.
How does CJC-1295 ipamorelin work?
CJC-1295 acts on the growth-hormone-releasing-hormone receptor while ipamorelin acts on the ghrelin receptor — two different doors to the same result, more growth hormone [1]. The pharmacological rationale for combining them is that these distinct, complementary mechanisms could produce a larger or more sustained growth-hormone response than either alone. That logic rests on each agent's single-agent pharmacology, not on any combination trial.
How much CJC-1295 ipamorelin should I take?
No controlled trial has ever tested the CJC-1295 ipamorelin combination, so there is no evidence-based dose [11]. The only repeated-dosing human ipamorelin data come from a failed hospital intravenous protocol [3], and the only other human data are acute pharmacokinetic infusions [2]. Recent reviews recommend confining ipamorelin to rigorous research protocols [16]. This site reports what was studied and does not provide a dose to take.
Does CJC-1295 ipamorelin work?
Each component has single-agent pharmacology supporting an acute growth-hormone response, and the combination's rationale is additive mechanisms [1]. But it has not been shown to "work" for body composition, recovery, or anti-aging in any controlled combination trial. Reviews characterize growth hormone secretagogues as outrunning their evidence [11] and classify ipamorelin as investigational with no reproducible human outcome data [16].
How to reconstitute CJC-1295 ipamorelin 5mg?
Ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and freeze-thaw, so solution is typically refrigerated. These are general handling notes from the research-supply literature, not preparation instructions — and research-grade material from unregulated suppliers has unverified identity, purity, and sterility [17]. This site does not provide preparation or injection guidance.
How long does ipamorelin stay in your system?
Ipamorelin clears quickly: a terminal half-life of about 2 hours in healthy human volunteers, with a single growth-hormone pulse peaking near 40 minutes after dosing [2]. By the usual five-half-life rule of thumb, the parent peptide is largely cleared within roughly 10 hours — but validated anti-doping methods still detect it and its metabolites in urine at picogram levels [7][9]. See the half-life page for detail.
Does ipamorelin make you hungry?
Sometimes. Ipamorelin acts on the ghrelin receptor — the body's own hunger-signal receptor — so an appetite bump is mechanistically plausible [15], and increased hunger is occasionally reported in the hours after dosing. A 2026 sports-medicine review classifies ipamorelin as an investigational secretagogue [16]; community accounts call the appetite effect milder than with GHRP-6. No human appetite data exist at research-use doses.
Will I gain weight on ipamorelin?
There is no human trial answering this directly. In mice, ipamorelin increased fat mass and leptin partly independent of the growth-hormone axis after two weeks [14], and ghrelin-receptor agonists drive feeding [15] — so weight gain is mechanistically possible through appetite. But the only human efficacy trial concerned bowel recovery, not body weight, and reported no compound-specific signal [3]. Community reports are mixed and anecdotal.
Does ipamorelin increase appetite?
It can, by mechanism. Ipamorelin activates the ghrelin receptor, and central ghrelin-receptor agonism activates the brain's appetite centers and induces feeding in animals [15]. A 2026 review treats ipamorelin as an investigational growth-hormone-axis secretagogue [16]. Appetite increase is among the occasionally-reported real-world effects, described as milder than with older peptides — but unverified by human data at research-use doses.
What does ipamorelin peptide do?
Ipamorelin peptide selectively activates the ghrelin receptor on pituitary cells to release a pulse of growth hormone, without meaningfully raising cortisol or prolactin [1]. In humans that pulse peaks about 40 minutes after dosing and clears with a ~2-hour half-life [2]. In rats it speeds bone growth [4]. Its real-world reputation for sleep and recovery is anecdotal; its one human efficacy trial failed [3].
How long does it take for ipamorelin to work?
Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes (0.67 h) after an intravenous dose in humans [2]. For the subjective effects people report — better sleep, recovery — community accounts describe first changes within one to two weeks of a routine, with body-composition shifts noted later, around weeks five to twelve. Those timelines are anecdotal, not from controlled studies, and vary widely.
Does ipamorelin cause water retention?
Mild water retention and puffiness are occasionally reported, usually in the first few weeks and generally described as milder than with older growth-hormone-releasing peptides. The mechanism is plausible: growth-hormone excess promotes sodium and water retention [6]. But this is an anecdotal community signal, not a finding from a controlled ipamorelin trial — the one Phase 2 trial recorded no compound-specific safety signal in its short window [3].